Intrarosa

Prasterone, the active ingredient in Intrarosa, is an androgen (steroid hormone) presented as a vaginal insert for vaginal use. It is indicated for the treatment of dyspareunia caused by vulvar and vaginal atrophy in postmenopausal women, helping to restore tissue integrity and lubrication. GNH USA supplies Intrarosa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches for global distribution.

Intrarosa (prasterone) is used to address vulvovaginal atrophy, a condition associated with postmenopausal estrogen deficiency.

Dyspareunia due to vulvar and vaginal atrophy: reduces pain during intercourse by improving vaginal lubrication and epithelial health. Vaginal dryness associated with atrophy: increases moisture and comfort during daily activities. Vulvar irritation linked to atrophic changes: promotes tissue thickness and reduces irritation.

Intrarosa may cause a range of adverse reactions.

Common Side Effects: - Vaginal discharge or spotting. - Mild abdominal or pelvic discomfort. - Headache. - Nausea. - Breast tenderness. - Local irritation at the insertion site.

Serious or Rare Side Effects: - Unexplained vaginal bleeding. - Endometrial hyperplasia. - Severe abdominal pain. - Allergic reaction such as rash, itching, or swelling. - Signs of hormonal imbalance (e.g., hirsutism, voice changes).

Before using Intrarosa, consider the following safety measures.

Pregnancy: safety not established; avoid use in pregnant women. Breastfeeding: unknown effects; weigh potential risks. Hormone‑sensitive conditions: use with caution in patients with estrogen‑dependent tumors. Concomitant estrogen therapy: may increase systemic hormone exposure. Allergy: discontinue if hypersensitivity reactions occur. Store at room temperature: keep in original packaging, protect from moisture and heat.

Intrarosa can interact with other hormonal or metabolic agents.

Major Interactions (Avoid): - Systemic estrogen therapy: may raise overall hormone levels. - Androgenic drugs: additive hormonal effects. - Strong CYP3A4 inhibitors: could increase local metabolite concentrations.

Moderate Interactions (Monitor Closely): - Vaginal antifungal preparations: may affect drug absorption. - Hormonal contraceptives: monitor for altered efficacy. - Other vaginal inserts or medications: avoid concurrent use to prevent interference.